For the last twenty years, prof. dr. Rottey is involved in international high-level research towards novel therapeutic options for patients with various solid tumors. In this matter, immunotherapy is becoming the state of the art for therapy of several solid tumors. As prof. dr. Rottey is leading phase I oncology clinical trials for the last decade, she has worked and continues to work with different immunotherapies in development. Next, prof. dr. Rottey is continuously involved in high-quality state of the art research for both novel therapeutic options for patients with solid tumors (both genitourinary; namely urothelial carcinoma, renal cell carcinoma and prostate cancer; and head and neck tumors) as well as new diagnostic biomarkers that could have predictive and prognostic value in these patient populations.